Curcumin has ignited global interest as an elite drugable molecule, owing to its time-honoured pharmacological activities against diverse human ailments. Limited natural accessibility and poor oral bioavailability caused major hurdles in the curcumin-based drug development process. We report the first successful testimony of curcumin and its glucoside synthesis in Atropa belladonna hairy roots (HR) through metabolic engineering. Re-routing the inherent biosynthetic precursors of the phenylpropanoid pathway of A. belladonna by heterologous expression of key curcumin biosynthetic pathway genes (i.e., Diketide-CoA synthase-DCS and Curcumin synthase-CURS3) and glucosyltransferase gene (CaUGT2) resulted in the production of curcumin and its glucoside in HR clones. Under shake-flask cultivation, the PGD2-HR1clone bearing DCS/ CURS3 genes showed the maximum curcumin yield (180.62 ± 4.7 µg/g DW), while the highest content of curcumin monoglucoside(32.63 ± 2.27 µg/g DW) along with curcumin (67.89 ± 2.56 µg/g DW) were noted in the PGD3-HR3 clone co-expressing DCS/CURS3 and CaUGT2 genes. Bioreactor up-scaling showed yield improvements in the PGD2-HR1 (2.3 fold curcumin) and the PGD3-HR3 clone (0.9 and 1.65 folds of curcumin-monoglucosideand curcumin respectively). These findings proved the advantageous use of HR cultures as the production source for curcumin and its glucoside, which remained unexplored so far.

姜黄素作为一种优秀的可药物分子，由于其对各种人类疾病的悠久药理活性而引起了全球的兴趣。有限的自然可及性和较差的口服生物利用度在基于姜黄素的药物开发过程中造成了主要障碍。我们通过代谢工程报告了姜黄素及其糖苷在颠茄毛根 (HR) 中合成的第一个成功证据。重路由的苯丙素途径的固有生物合成的前体A.颠茄通过键姜黄素生物合成途径的基因的异源表达（即，二酮-CoA合酶- DCS和姜黄素合酶- CURS3和葡糖基因（）CaUGT2 ) 导致在 HR 克隆中产生姜黄素及其糖苷。在摇瓶培养下，携带DCS / CURS3基因的 PGD2-HR1clone表现出最大的姜黄素产量（180.62 ± 4.7 µg/g DW），而姜黄素单糖苷的含量最高（32.63 ± 2.27 µg/g DW）以及姜黄素（在共表达DCS / CURS3和CaUGT2的 PGD3-HR3 克隆中注意到 67.89 ± 2.56 µg/g DW）基因。生物反应器放大显示 PGD2-HR1（姜黄素 2.3 倍）和 PGD3-HR3 克隆（姜黄素-单糖苷和姜黄素分别为 0.9 和 1.65 倍）的产量提高。这些发现证明了将 HR 培养物用作姜黄素及其糖苷的生产来源的有利用途，到目前为止，这仍然是未开发的。